rabeprazole

Action and Spectrum

Action and Spectrum 

It is a medication that falls into the category of proton pump inhibitors (PPIs). It works by binding to the proton pump in gastric parietal cells, ultimately reducing acid secretion. This oral drug is commonly used to treat conditions linked to acid overproduction in the stomach. 

Drug Interaction

Adverse Reaction

Frequency defined 

1-10 % 

Pain (3%) 

Constipation (2%) 

Flatulence (3%) 

Pharyngitis (3%) 

Diarrhea (2-5%) 

Headache (2-10%) 

Abdominal pain (4%) 

<1% 

Hypokalemia 

Sudden death 

Leukocytosis 

Hypomagnesemia 

Angioedema 

Toxic epidermal necrolysis 

Migraine 

Agranulocytosis 

Alopecia 

Rhabdomyolysis 

Abnormal taste 

Osteoporosis related fracture 

Erythema multiforme 

Chest pain 

Delirium 

Jaundice 

Leukopenia 

Anemia 

Stevens-Johnson syndrome 

Agitation 

Hyponatremia 

Postmarketing reports 

Disorders affecting the renal and urinary systems: Interstitial nephritis, erectile dysfunction 

Disorders related to metabolism and nutrition: Hyperammonemia 

Disorders of the blood and lymphatic system: Hemolytic anemia, pancytopenia, thrombocytopenia 

Disorders affecting the respiratory, thoracic, and mediastinal regions: Interstitial pneumonia 

Deficiency condition: Cyanocobalamin (vitamin B-12) deficiency 

Investigative findings: Increases in prothrombin time/INR (in patients treated with concomitant warfarin), TSH elevations 

Disorders of the nervous system: Coma 

Disorders of the ear and labyrinth: Vertigo 

Disorders of the eye: Blurred vision 

Infections and infestations: Clostridium difficile-associated diarrhea 

Disorders of the psyche: Disorientation 

Disorders of the immune system: Anaphylaxis, toxic epidermal necrolysis (some fatal), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) 

Gastrointestinal disorders: Fundic gland polyps 

Disorders of the musculoskeletal system: Bone fracture 

Cutaneous and systemic lupus erythematosus 

Disorders affecting the skin and subcutaneous tissues: Severe dermatologic reactions including bullous and other drug eruptions of the skin 

Black Box Warning

Black Box Warning: 

None 

Contraindication / Caution

Contraindication/Caution: 

Contraindications 

• Hypersensitivity 
• Rilpivirine containing products 

Cautions 

• Renal impairment 
• Gastric malignancy 
• Acute tubulointerstitial nephritis 
• Bone fracture 
• Cyanocobalamin deficiency 
• CLE 
• SLE 
• Use with warfarin 
• Clostridium difficile-Asociated diarrhea 
• Severe cutaneous adverse reactions 
• Hypomagnesemia 
• Fundic Gland Polyps 
• Hepatic impairment 
• Drug interactions 
• Pregnancy  
• Breastfeeding 

Pregnancy / Lactation

Pregnancy consideration:  

No data is available regarding the administration of the drug during pregnancy. 

Breastfeeding warnings:  

No data is available regarding the excretion of drug in breast milk. 

Pregnancy category: 

Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    

Category N: No data is available for the drug under this category. 

Pharmacology

Pharmacology 

It suppresses basal and induced gastric acid output in a dose-dependent manner by inhibiting the hydrogen ions, pottasium ions, ATPase of the coated stomach cells. 

Pharmacodynamics: 

It is a gastric proton pump inhibitor, is employed in the treatment of gastrointestinal ulcers, GERD symptoms.  

Pharmacokinetics: 

Absorption 

The bioavailability is 52% 

The time to achieve peak effect is 2-5 hours 

Distribution 

Protein-bound is 96.3% 

Metabolism 

Hepatic metabolism 

Elimination and Excretion 

The drug is excreted 10% in feces and 90 % in urine. 

Half-life: 1-2 hour 

Adminstartion

Administration: 

It is administered orally before thirty minutes of meals. 

Patient Information Leaflet

Patient information leaflet  

Generic Name: rabeprazole 

Pronounced:   

Why do we use rabeprazole?  

Rabeprazole is a proton pump inhibitor (PPI) that reduces stomach acid production and is used to treat various acid-related gastrointestinal conditions. It is commonly prescribed for gastroesophageal reflux disease (GERD), healing erosive esophagitis, and managing gastric and duodenal ulcers. In cases of Helicobacter pylori infection, it is used with antibiotics to promote ulcer healing. Rabeprazole is also indicated for Zollinger-Ellison syndrome and the prevention of NSAID-induced gastric ulcers. Off-label, it may be used for functional dyspepsia and stress ulcer prevention in high-risk patients.